Zevra Therapeutics (ZVRA) Competitors

Zevra Therapeutics logo
$9.20 -0.05 (-0.52%)
As of 01:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ZVRA vs. HCM, RGC, PRGO, PBH, and HRMY

Should you buy Zevra Therapeutics stock or one of its competitors? Zevra Therapeutics's main competitors and comparable companies include HUTCHMED (HCM), Regencell Bioscience (RGC), Perrigo (PRGO), Prestige Consumer Healthcare (PBH), and Harmony Biosciences (HRMY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zevra Therapeutics compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

HUTCHMED has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

HUTCHMED has higher revenue and earnings than Zevra Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED$549.12M4.68$456.91MN/AN/A
Zevra Therapeutics$106.47M5.17$83.23M$1.197.77

In the previous week, Zevra Therapeutics had 15 more articles in the media than HUTCHMED. MarketBeat recorded 19 mentions for Zevra Therapeutics and 4 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.34 beat Zevra Therapeutics' score of 0.01 indicating that HUTCHMED is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HUTCHMED
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral

Zevra Therapeutics has a net margin of 52.80% compared to HUTCHMED's net margin of 0.00%. Zevra Therapeutics' return on equity of 54.64% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMEDN/A N/A N/A
Zevra Therapeutics 52.80%54.64%37.84%

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HUTCHMED presently has a consensus target price of $14.87, suggesting a potential upside of 0.93%. Zevra Therapeutics has a consensus target price of $23.86, suggesting a potential upside of 157.92%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Zevra Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Zevra Therapeutics beats HUTCHMED on 11 of the 14 factors compared between the two stocks.

How does Zevra Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Zevra Therapeutics has a net margin of 52.80% compared to Regencell Bioscience's net margin of 0.00%. Zevra Therapeutics' return on equity of 54.64% beat Regencell Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Zevra Therapeutics 52.80%54.64%37.84%

Zevra Therapeutics has higher revenue and earnings than Regencell Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$11.70MN/AN/A
Zevra Therapeutics$106.47M5.17$83.23M$1.197.77

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Regencell Bioscience has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Zevra Therapeutics has a consensus target price of $23.86, suggesting a potential upside of 157.92%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Zevra Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Zevra Therapeutics had 17 more articles in the media than Regencell Bioscience. MarketBeat recorded 19 mentions for Zevra Therapeutics and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 1.45 beat Zevra Therapeutics' score of 0.01 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regencell Bioscience
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

Zevra Therapeutics beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks.

How does Zevra Therapeutics compare to Perrigo?

Perrigo (NYSE:PRGO) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Perrigo presently has a consensus target price of $18.50, indicating a potential upside of 14.44%. Zevra Therapeutics has a consensus target price of $23.86, indicating a potential upside of 157.92%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
Zevra Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.00

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Perrigo has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

In the previous week, Zevra Therapeutics had 16 more articles in the media than Perrigo. MarketBeat recorded 19 mentions for Zevra Therapeutics and 3 mentions for Perrigo. Perrigo's average media sentiment score of 0.21 beat Zevra Therapeutics' score of 0.01 indicating that Perrigo is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral

Zevra Therapeutics has a net margin of 52.80% compared to Perrigo's net margin of -43.27%. Zevra Therapeutics' return on equity of 54.64% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-43.27% 12.39% 4.07%
Zevra Therapeutics 52.80%54.64%37.84%

Zevra Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.25B0.53-$1.43B-$12.76N/A
Zevra Therapeutics$106.47M5.17$83.23M$1.197.77

Summary

Zevra Therapeutics beats Perrigo on 14 of the 17 factors compared between the two stocks.

How does Zevra Therapeutics compare to Prestige Consumer Healthcare?

Zevra Therapeutics (NASDAQ:ZVRA) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Zevra Therapeutics had 17 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 19 mentions for Zevra Therapeutics and 2 mentions for Prestige Consumer Healthcare. Zevra Therapeutics' average media sentiment score of 0.01 beat Prestige Consumer Healthcare's score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
Prestige Consumer Healthcare
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Zevra Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Prestige Consumer Healthcare has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zevra Therapeutics$106.47M5.17$83.23M$1.197.77
Prestige Consumer Healthcare$1.09B2.09$190.30M$3.2414.81

Zevra Therapeutics has a net margin of 52.80% compared to Prestige Consumer Healthcare's net margin of 13.29%. Zevra Therapeutics' return on equity of 54.64% beat Prestige Consumer Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics52.80% 54.64% 37.84%
Prestige Consumer Healthcare 13.29%11.28%5.25%

Zevra Therapeutics presently has a consensus price target of $23.86, suggesting a potential upside of 157.92%. Prestige Consumer Healthcare has a consensus price target of $67.00, suggesting a potential upside of 39.62%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zevra Therapeutics is more favorable than Prestige Consumer Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.00
Prestige Consumer Healthcare
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Zevra Therapeutics beats Prestige Consumer Healthcare on 12 of the 17 factors compared between the two stocks.

How does Zevra Therapeutics compare to Harmony Biosciences?

Zevra Therapeutics (NASDAQ:ZVRA) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Zevra Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Zevra Therapeutics has a net margin of 52.80% compared to Harmony Biosciences' net margin of 18.05%. Zevra Therapeutics' return on equity of 54.64% beat Harmony Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics52.80% 54.64% 37.84%
Harmony Biosciences 18.05%18.55%13.24%

Harmony Biosciences has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zevra Therapeutics$106.47M5.17$83.23M$1.197.77
Harmony Biosciences$868.45M2.23$158.69M$3.0210.91

Zevra Therapeutics currently has a consensus price target of $23.86, indicating a potential upside of 157.92%. Harmony Biosciences has a consensus price target of $48.00, indicating a potential upside of 45.63%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.00
Harmony Biosciences
1 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.54

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Zevra Therapeutics had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 19 mentions for Zevra Therapeutics and 17 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.33 beat Zevra Therapeutics' score of 0.01 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zevra Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
Harmony Biosciences
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Zevra Therapeutics beats Harmony Biosciences on 9 of the 16 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVRA vs. The Competition

MetricZevra TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$548.09M$13.63B$7.76B$11.63B
Dividend YieldN/A2.58%2.46%4.43%
P/E Ratio7.7429.4734.2929.91
Price / Sales5.147.018.485.64
Price / Cash11.8015.7421.9322.50
Price / Book2.295.114.393.67
Net Income$83.23M$2.88B$3.51B$392.03M
7 Day Performance-22.80%-3.90%-5.19%-3.98%
1 Month Performance-7.42%-4.91%-4.33%-6.46%
1 Year Performance0.24%-7.41%-1.33%-6.95%

Zevra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVRA
Zevra Therapeutics
3.873 of 5 stars
$9.20
-0.5%
$23.86
+159.3%
+4.2%$548.09M$106.47M7.7461
HCM
HUTCHMED
0.8777 of 5 stars
$14.90
+0.3%
$14.87
-0.2%
-2.3%$2.59B$549.12MN/A1,796
RGC
Regencell Bioscience
0.6447 of 5 stars
$4.94
-3.7%
N/A-62.5%$2.54BN/AN/A10
PRGO
Perrigo
2.0581 of 5 stars
$16.22
+0.3%
$18.50
+14.0%
+17.4%$2.25B$4.25BN/A8,100
PBH
Prestige Consumer Healthcare
2.8165 of 5 stars
$46.05
+1.6%
$67.00
+45.5%
-20.0%$2.15B$1.09B14.21890

Related Companies and Tools


This page (NASDAQ:ZVRA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners